Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Searle's Maxaquin

Executive Summary

Company's once-daily oral quinolone antimicrobial drug lomefloxacin will be subject of a March 31 joint meeting of FDA's Anti-Infective and Dermatologic Drugs Advisory Committees. "Recent reports of phototoxicity thought to be associated with the use of lomefloxacin" and a recent Roche-sponsored animal photocarcinogenicity study in which Maxaquin "appears to act as a dermal tumor promoter" will be discussed as to their relevance to humans, regulatory options for the drug and options for information dissemination. Maxaquin was approved Feb. 21, 1992 ("The Pink Sheet" March 2, 1992, T&G-1). Meeting begins at 8:30 a.m. at the Holiday Inn, Silver Spring, Md.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel